GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Interest Coverage

Revelation Biosciences (FRA:56U0) Interest Coverage : No Debt (1) (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Revelation Biosciences's Operating Income for the three months ended in Dec. 2023 was €-2.13 Mil. Revelation Biosciences's Interest Expense for the three months ended in Dec. 2023 was €0.00 Mil. Revelation Biosciences has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Revelation Biosciences Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Revelation Biosciences's Interest Coverage or its related term are showing as below:

FRA:56U0' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


FRA:56U0's Interest Coverage is ranked better than
99.41% of 340 companies
in the Biotechnology industry
Industry Median: 138.73 vs FRA:56U0: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Revelation Biosciences Interest Coverage Historical Data

The historical data trend for Revelation Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Revelation Biosciences Interest Coverage Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Coverage
No Debt No Debt No Debt No Debt

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of Revelation Biosciences's Interest Coverage

For the Biotechnology subindustry, Revelation Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Interest Coverage falls into.



Revelation Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Revelation Biosciences's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Revelation Biosciences's Interest Expense was €0.00 Mil. Its Operating Income was €-7.94 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

Revelation Biosciences had no debt (1).

Revelation Biosciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Revelation Biosciences's Interest Expense was €0.00 Mil. Its Operating Income was €-2.13 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

Revelation Biosciences had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Revelation Biosciences  (FRA:56U0) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Revelation Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines